In
Insilico Medicine
Hong Kong CNFounded 2014350 employees
Private CapbiotechPrivateOncology
Platform: Pharma.AI
Market Cap
N/A
All Drugs
4
Clinical Trials
7
Failed / Terminated
1
FDA Approved
0
Drug Pipeline (4 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| INS-6048 | INS-6048 | NDA/BLA | 2 | CD20 | Hemophilia A | ||
| Rilutenlimab | INS-1085 | Preclinical | 2 | B7-H3 | SchizophreniaRSV | ||
| INS-8557 | INS-8557 | Phase 2/3 | 1 | TNFα | NarcolepsyGastric Ca | ||
| INS-408 | INS-408 | Phase 1 | 2 | WRN | GISTLGS |
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (6)